Search company, investor...

NovaDigm Therapeutics

novadigm.net

Stage

Series B | Alive

Total Raised

$35.16M

Last Raised

$14M | 9 yrs ago

About NovaDigm Therapeutics

NovaDigm Therapeutics is developing vaccines to protect patients from fungal and bacterial infections, which can be life-threatening and drug resistant. The company's lead product candidate, NDV-3, is a recombinant glycoprotein vaccine containing a candidal surface antigen, agglutinin-like sequence 3 protein or Als3. Results from a Phase 1 clinical trial demonstrated that a single dose of the NDV-3 vaccine was safe, well-tolerated and induced strong antibody and T-cell immune responses in healthy adults.

Headquarters Location

4201 James Ray Drive Suite 2200

Grand Forks, North Dakota, 58202,

United States

701-757-5161

Missing: NovaDigm Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NovaDigm Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing NovaDigm Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NovaDigm Therapeutics is included in 2 Expert Collections, including Regenerative Medicine.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

NovaDigm Therapeutics Patents

NovaDigm Therapeutics has filed 5 patents.

The 3 most popular patent topics include:

  • Animal fungal diseases
  • Bacterial diseases
  • Infectious diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/7/2017

12/8/2020

Piperazines, Antifungals, Animal fungal diseases, Pregnanes, Fluoroarenes

Grant

Application Date

3/7/2017

Grant Date

12/8/2020

Title

Related Topics

Piperazines, Antifungals, Animal fungal diseases, Pregnanes, Fluoroarenes

Status

Grant

Latest NovaDigm Therapeutics News

Candidiasis Market Size & Trends 2020 – expected to reach US$ 1,307.2 Million With CAGR of 4.6% by 2026, Owing Increasing Prevalence of Candidiasis

Mar 2, 2021

Search jobs 02-Mar-2021 Candidiasis Market Size & Trends 2020 – expected to reach US$ 1,307.2 Million With CAGR of 4.6% by 2026, Owing Increasing Prevalence of Candidiasis Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Global Candidiasis Market , by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at US$ 873.8 million in 2017, and is projected to exhibit a CAGR of 4.6% over the forecast period (2018–2026), as highlighted in a new report published by Coherent Market Insights. Request for the trending sample of this report: https://www.coherentmarketinsights.com/insight/request-sample/229 Increasing prevalence of candidiasis is expected to fuel growth of the global candidiasis market over the forecast period. For instance, according to the study, ‘National Burden of Candidemia, United States, 2017, published in November 2018, in the journal Open Forum Infectious Diseases, invasive candidiasis (candidemia) is one of the most common bloodstream infections in the U.S. and the average incidence for the disease was around 9 per 100,000 people during 2013–2017. R&D of new vaccines for the treatment of candidiasis is expected to boost growth of the global candidiasis market over the forecast period. For instance, in August 2019, researchers from the Los Angeles Biomedical Research Institute (LA BioMed), a spinoff company of NovaDigm Therapeutics, started developing the vaccine-NDV-3A to prevent infections caused by C. auris in humans, after successfully immunizing and demonstrating its clinical efficacy in mice. Quick Buy – Candidiasis Market Research Report: https://www.coherentmarketinsights.com/insight/buy-now/229 Increasing number of clinical trials related to the treatment of fungal diseases is expected to propel growth of the global candidiasis market. For instance, in 2017, the University Hospital of Cologne initiated a clinical trial to evaluate drug candidate SCY-078 in patients with fungal diseases that are refractory to or intolerant of standard antifungal treatment, in Europe. Major players in the market are focused on adopting M&A strategies to expand their product portfolio. For instance, in March 2018, Viamet Pharmaceuticals (NC), Inc. acquired Viamet Pharmaceuticals. The acquisition included the company’s product candidate, VT-1161, which successfully completed Phase 2b clinical trials for the treatment of recurrent vulvovaginal candidiasis (RVVC) and onychomycosis, or fungal nail infection. Similarly, in 2014, NovaDigm Therapeutics acquired the rights to three Candida vaccine antigens from the Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center. Browse 40 Market Data Tables and 38 Figures spread through 178 Pages and in-depth TOC on “Candidiasis Market”- Global Forecast to 2026 by Drug Class (Azoles, Echinocandins, Polyenes, and Flucytosine), by Type (Candida Infections of the Mouth, Throat, and Esophagus, Vaginal Candidiasis, and Invasive/Systemic Candidiasis), By Route of Administration (Oral, Parenteral, and Topical), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) To know the latest trends and insights prevalent in the global candidiasis market press release, click the link below: https://www.coherentmarketinsights.com/press-release/candidiasis-market-to-surpass-us-13072-million-by-2026-2454 Key Takeaways The global candidiasis market is expected to exhibit a CAGR of 4.6% over the forecast period Among drug class, the azoles segment held dominant position in the global candidiasis market in 2017. Azoles are considered as the first-line agents in the treatment of various types of candidiasis such as esophageal and vaginal candidiasis. Among type, the vaginal candidiasis segment held dominant position in the global candidiasis market in 2017, owing to R&D in this segment Among route of administration, the oral segment held dominant position in the global candidiasis market in 2017. Several antifungal drugs used for the treatment and management of candidiasis are available in oral dosage form. Major players operating in the global candidiasis market include Basilea Pharmaceutica Ltd., Astellas Pharma Inc., Grupo Ferrer Internacional, S.A., Pacgen Life Science Corporation, NovaDigm Therapeutics, Inc., Cidara Therapeutics, Inc., Amplyx Pharmaceuticals Inc., and Pfizer, Inc. Got any Query? Feel free to ask us at https://www.coherentmarketinsights.com/insight/talk-to-analyst/229 About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services. To know more about us, please visit our website –  www.coherentmarketinsights.com Contact:

NovaDigm Therapeutics Frequently Asked Questions (FAQ)

  • Where is NovaDigm Therapeutics's headquarters?

    NovaDigm Therapeutics's headquarters is located at 4201 James Ray Drive, Grand Forks.

  • What is NovaDigm Therapeutics's latest funding round?

    NovaDigm Therapeutics's latest funding round is Series B.

  • How much did NovaDigm Therapeutics raise?

    NovaDigm Therapeutics raised a total of $35.16M.

  • Who are the investors of NovaDigm Therapeutics?

    Investors of NovaDigm Therapeutics include Domain Associates.

  • Who are NovaDigm Therapeutics's competitors?

    Competitors of NovaDigm Therapeutics include Immunomic Therapeutics, Adamas Pharmaceuticals, Phico Therapeutics, Intarcia Therapeutics, CoImmune and 16 more.

Compare NovaDigm Therapeutics to Competitors

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

A
Avidimer Therpeutics

Avidimer Therapeutics is engaged in the discovery and development of therapeutics for inflammatory diseases

T
Traversa Therapeutics

Traversa Therapeutics is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi anti-cancer therapeutics. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of platform delivery technology, as well as advancement of therapeutic programs for the treatment of leukemia and glioblastoma.

A
Actinobac Biomed

Actinobac Biomed is a biopharmaceutical company developing therapeutics for multiple indications, including blood cancers, autoimmune/inflammatory diseases, and HIV. Its drug candidates are based upon Leukothera (LtxA), a natural protein that targets and eliminates white blood cells (WBCs) involved in the mechanism of many diseases. Products based upon Leukothera are being developed by Actinobac for the treatment of leukemia/lymphoma, dry eye, and psoriasis.

BlueWillow Biologics Logo
BlueWillow Biologics

BlueWillow Biologics develops nasal vaccines and immunotherapy to protect global populations from respiratory infections, sexually transmitted diseases, and food allergies. The company's novel intranasal NanoVax adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. BlueWillow Biologics was formerly known as NanoBio. The company was founded in 1999 and is based in Ann Arbor, Michigan.

M
MAKScientific

is engaged in endocannabinoid research with the ability to address major unmet medical needs for selected diseases with clear competitive advantage over present therapies. The company's mission is the discovery, development and commercialization of therapeutics in the areas of neuropathic, inflammatory and somatic pain, obesity, neuroprotection, and addiction and glaucoma.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.